2025-09-06 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data. The report is structured with key metrics first, followed by a detailed analysis of each data point, and a concluding summary.

## JNJ Stock Analysis

### 1. Performance Overview

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Description:** A multinational corporation that manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **Cumulative Return:** 30.16%
*   **VOO (S&P 500) Cumulative Return:** 101.31%
*   **Relative Deviation:** -69.4 (Relative Deviation Percentile: 13.2)

    *   Deviation Range: Min: -83.0, Max: 20.0

**Analysis:** JNJ's cumulative return significantly underperforms the S&P 500 (VOO) over the analyzed period. The relative deviation suggests JNJ's performance is closer to its historical minimum compared to VOO. The relative deviation percentile of 13.2 means that JNJ's current performance compared to VOO is in the bottom 13.2% of its historical range.

### 2. Alpha, Beta, and Risk Analysis

| Year        | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
| ----------- | ------- | ------- | ------- | ------ | ------ |
| 2015-2017   | 28.0%   | 56.1%   | -1.0%   | -0.0   | 336.5  |
| 2016-2018   | 8.0%    | 56.6%   | -10.0%  | 0.0    | 310.8  |
| 2017-2019   | 18.0%   | 56.6%   | -12.0%  | 0.7    | 351.3  |
| 2018-2020   | 12.0%   | 59.2%   | -8.0%   | 0.3    | 379.0  |
| 2019-2021   | 32.0%   | 59.6%   | -16.0%  | 0.2    | 412.0  |
| 2020-2022   | 7.0%    | 61.4%   | 5.0%    | 0.2    | 425.4  |
| 2021-2023   | -15.0%  | 61.4%   | -33.0%  | 0.4    | 377.5  |
| 2022-2024   | -35.0%  | 61.4%   | -61.0%  | 0.3    | 348.3  |
| 2023-2025   | 3.0%    | 70.1%   | -50.0%  | 0.2    | 429.7  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Varies significantly, with negative growth in recent periods (2021-2025).
*   **MDD (Maximum Drawdown):**  High MDD indicates significant potential for losses during downturns.  The MDD has been increasing, reaching 70.1% recently, showing growing downside risk.
*   **Alpha:**  Mostly negative, indicating underperformance relative to the market risk-free rate.  The negative Alpha has become significantly more pronounced in recent years.
*   **Beta:** Generally low (close to zero), suggesting JNJ has low volatility compared to the market.
*   **Cap(B) (Market Cap in Billions):**  Illustrates the company's size.

### 3. Recent Price Action

*   **Current Price:** 178.43
*   **Previous Close:** 178.76
*   **Change:** -0.18
*   **5-Day Moving Average:** 177.86
*   **20-Day Moving Average:** 176.66
*   **60-Day Moving Average:** 165.55

**Analysis:** The stock price experienced a minor decrease. The 5-day moving average is above the 20-day moving average, which is above the 60-day moving average, suggesting a short-term upward trend.

### 4. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 57.49 (Neutral)
*   **PPO:** -0.28 (Neutral)
*   **Hybrid Signal:** cash_67%_Sell 4.0% of holdings (13 shares - Caution - MRI:0.34)
*   **Delta_Previous_Relative_Divergence:** 0.0 (Negative - Short-Term Decrease)
*   **Expected Return (%):** -209.2% (Long-Term, Relative to S&P 500)

**Analysis:**

*   **MRI:** Indicates a low level of market risk.
*   **RSI:**  Is in a neutral zone.
*   **PPO:** Suggests a potential downward trend, but is relatively neutral.
*   **Hybrid Signal:** The signal suggests a cautious approach, recommending holding a high cash position and selling a small portion of holdings.
*   **Relative Divergence:**  Indicates a short-term downward trend.
*   **Expected Return:**  Extremely negative, indicating significant underperformance compared to the S&P 500 if investing from this point.

### 5. Recent News & Significant Events

*   **Kenvue Stock Tumbles:** Report linking autism and Tylenol impacts Kenvue (Barrons.com).  (Note: Kenvue is a spin-off from JNJ's consumer health division.)
*   **Ronovo Surgical Closes Series D Financing:** (Business Wire)
*   **BDTX Stock Surges:**  Positive news related to BDTX (Zacks).
*   **Acetaminophen Market Trends:** Growth in acetaminophen market (GlobeNewswire).
*   **Campbell’s Appoints New SVP:**  (Business Wire)
*   **BDTX Pipeline Progress:**  Positive pipeline progress for BDTX's NSCLC drug (Zacks).

**Analysis:** The most concerning news item is the report linking autism and Tylenol, which is impacting Kenvue.  This could indirectly affect JNJ's reputation and potentially raise concerns about other consumer products. The other news items are more general market or company-specific developments.

### 6. Analyst Opinions

*   **Consensus:** Buy (Mean Rating: 2.25)
*   **Opinions:** 23 Analysts
*   **Target Price:**
    *   Average: 177.47
    *   High: 200.00
    *   Low: 155.00
*   **Recent Rating Changes:** No specific changes provided.

**Analysis:** The analyst consensus is "Buy," but the average target price is slightly below the current price. This suggests that analysts see limited upside potential in the near term, or they are revising their price targets downwards.

### 7. Earnings Analysis

| 날짜       | EPS  | 매출        |
| ---------- | ---- | ----------- |
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2024-07-25 | 1.95 | 22.45 B$    |
| 2025-07-24 | 1.95 | 22.45 B$    |

**Analysis:**

*   Revenue and EPS (Earnings Per Share) fluctuate.
*   Most recent EPS is lower compared to the previous quarter.

### 8. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | --------------- |
| 2025-06-30 | $23.74B   | 67.87%          |
| 2025-03-31 | $21.89B   | 66.40%          |
| 2024-12-31 | $22.52B   | 68.35%          |
| 2024-09-30 | $22.47B   | 69.01%          |
| 2024-06-30 | $22.45B   | 69.40%          |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | ------- |
| 2025-06-30 | $78.47B   | 7.06%   |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |

**Analysis:**

*   **Revenue:** Relatively stable, with a slight increase in the most recent quarter.
*   **Profit Margin:** Consistently high.
*   **Equity:** Increasing.
*   **ROE (Return on Equity):** Fluctuating, but generally positive.

### 9. Overall Summary

Based on the provided data, Johnson & Johnson (JNJ) presents a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, and the expected return relative to the S&P 500 is substantially negative.
*   **Risk:** MDD has increased, signaling rising downside risk.
*   **Price Action:** Recent price action suggests a potential short-term upward trend.
*   **Market Risk:** The MRI indicates a low level of market risk.
*   **Analyst Opinions:** The analyst consensus is "Buy," but the average target price is close to the current price.
*   **Financials:**  Revenue and profit margins are robust, but ROE is fluctuating.
*   **News:** The news regarding a potential link between Tylenol (associated with Kenvue, a JNJ spin-off) and autism is a concern and could impact the stock.

**Conclusion:**

While JNJ maintains a solid financial base with strong revenue and profitability, its underperformance relative to the market and the negative expected return are significant concerns. The recent news about Tylenol adds further uncertainty. The "Hold Cash/Sell" hybrid signal reflects the current cautious sentiment. A potential investor should weigh the company's strong financial fundamentals against the concerns raised by its underperformance, the negative expected return, and the recent negative news. Close monitoring of future earnings, news developments, and any updates to analyst ratings is crucial.
